Study on the value of 18F-FDG PET/CT in predicting short-term efficacy of CAR-T cell treatment in lymphoma patients
10.3969/j.issn.1002-1671.2025.01.033
- VernacularTitle:18F-FDG PET/CT预测淋巴瘤患者CAR-T细胞治疗后短期疗效的价值研究
- Author:
Jing HU
1
;
Yue DAI
;
Kai XU
Author Information
1. 徐州医科大学医学影像学院,江苏 徐州 221006
- Publication Type:Journal Article
- Keywords:
lymphoma;
chimeric antigen receptor-T;
18F-flu-orodeoxyglucose;
positron emission tomography/computed tomo-graphy;
short-term efficacy evaluation
- From:
Journal of Practical Radiology
2025;41(1):147-150
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of 18F-fluorodeoxyglucose(18F-FDG)PET/CT in predicting the short-term efficacy of chimeric antigen receptor(CAR)-T cell treatment in lymphoma patients.Methods The 18F-FDG PET/CT parameters[maximum standardized uptake value(SUVmax),total metabolic tumor volume(TMTV),total lesion glycolysis(TLG),and the maximum diam-eter of the maximum lesion(Dmax)]and serological indexes[β2-microglobulin(β2-MG)and lactate dehydrogenase(LDH)]of 30 lym-phoma patients before CAR-T cell treatment were analyzed retrospectively.The treatment efficacy was evaluated 4 weeks after CAR-T cell treatment,and all patients were divided into complete remission(CR)group and non-CR group to compare the differences in pre-treatment PET/CT parameters between the two groups.Binary logistic regression analysis was used to obtain the independent predictive factors for evaluating the short-term efficacy,and the optimal thresholds was determined via receiver operating characteristic(ROC)curve.Results Of 30 lymphoma patients 4 weeks after CAR-T cell treatment,there were 14 cases with CR and 16 cases with non-CR.There were statistical differences in SUVmax,TLG,Dmax and β2-MG between the two groups(P<0.05).SUVmax was the independent predictor for evaluating the short-term efficacy of CAR-T,with an optimal threshold of 12.5,an area under the curve(AUC)of 0.839,and the sensitivity and specificity was 87.5%and 78.6%,respectively.Conclusion Baseline 18F-FDG PET/CT parameters can be used to predict the short-term efficacy in lymphoma patients receiving CAR-T cell treatment,and SUVmax is an independent predictor for assessing short-term efficacy.
